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ABBREVIATION
TSC Tuberous sclerosis complex
AIM To investigate the interdependence between risk factors associated with long-term
intellectual development in individuals with tuberous sclerosis complex (TSC).
METHOD The Tuberous Sclerosis 2000 Study is a prospective longitudinal study of
individuals with TSC. In phase 1 of the study, baseline measures of intellectual ability,
epilepsy, cortical tuber load, and mutation were obtained for 125 children (63 females, 62
males; median age=39mo). In phase 2, at an average of 8 years later, intellectual abilities
were estimated for 88 participants with TSC and 35 unaffected siblings. Structural
equation modelling was used to determine the risk pathways from genetic mutation through
to IQ at phase 2.
RESULTS Intellectual disability was present in 57% of individuals with TSC. Individuals
without intellectual disability had significantly lower mean IQ compared to unaffected
siblings, supporting specific genetic factors associated with intellectual impairment.
Individuals with TSC who had a slower gain in IQ from infancy to middle childhood were
younger at seizure onset and had increased infant seizure severity. Structural
equation modelling indicated indirect pathways from genetic mutation, to tuber count, to
seizure severity in infancy, through to IQ in middle childhood and adolescence.
INTERPRETATION Early-onset and severe epilepsy in the first 2 years of life are associated
with increased risk of long-term intellectual disability in individuals with TSC, emphasizing
the importance of early and effective treatment or prevention of epilepsy.
Tuberous sclerosis complex (TSC) is a genetic disorder
caused by a mutation in the TSC1 or TSC2 genes. The TSC
proteins hamartin and tuberin form a heterodimeric com-
plex involved in intracellular signalling and the activation of
mammalian target of rapamycin complex 1, which plays an
important role in the regulation of cell proliferation and dif-
ferentiation.1 In addition to the primary mutation event,
stochastic second-hit mutations in the normal copy allele
during embryogenesis lead to marked upregulation of the
mammalian target of rapamycin pathway and consequently
the development of hamartomatous lesions and random
variation in the size and location of lesions, leading to highly
variable phenotypic expression. In the brain, subependymal
nodules in the ventricular walls and cortical tubers at the
grey–white matter interface arise and are associated with a
high risk of epilepsy, which occurs in up to 90% of individu-
als and typically begins in the first year of life. Epileptic
(infantile) spasms are common, but are often preceded by or
coexist with focal seizures.2 More than half of patients with
TSC have some form of intellectual impairment and
approximately one-third have profound disability, while a
significant proportion does not display impairment.3 A
bimodal distribution of IQ in individuals with TSC has
been reported,4 although whether this reflects a genotype–
phenotype correlation or the effect of epilepsy is unclear.5
With the advent of mammalian target of rapamycin inhibi-
tory treatment for several complications of TSC and specu-
lation that it may hold promise for improving cognitive
development, it has become especially important to charac-
terize the longitudinal pathways leading to intellectual
impairment in individuals with TSC, to identify the risk
processes that could be targets for treatment.
Intellectual development in individuals with TSC is
likely the result of a complex interplay of the wide range
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of identified risk factors. Several previous studies have
relied on univariate analyses of single predictors at single
time points. On a genetic level, TSC2 mutations are associ-
ated with a more severe phenotype, including lower intel-
lectual ability.6,7 Yet, profound disabilities can be observed
in individuals with a TSC1 mutation, as well as high IQ in
individuals with a TSC2 mutation. The extent of brain
involvement indexed by tuber count and load has also been
correlated with lower IQ;8–11 however, a large tuber bur-
den has been reported in individuals with normal IQ.12
Early-onset seizures and epileptic spasms are strongly asso-
ciated with intellectual disability in individuals with
TSC.12–14 Prospective longitudinal studies indicate poor
intellectual development in the first 2 years of life in
infants with spasms,15 and impaired development after the
onset of spasms compared to non-spasm seizures.16
Multifactorial analyses that can test the joint effects of
these risk factors have suggested that age at seizure onset
is the sole variable that can be used to independently pre-
dict intellectual outcome in children and adults.12,17 How-
ever, these previous analyses have relied on retrospective
reports and chart review to characterize epilepsy in clinic-
referred samples. Overcoming some of these limitations,
our previous multivariate analysis of IQ collected in the
longitudinal, prospective, and nationally ascertained
Tuberous Sclerosis 2000 Study cohort indicated an indirect
pathway linking the type of genetic mutation to cortical
tuber load, to epilepsy severity (latent factor for seizure
severity in the first 2 years of life and current seizure sever-
ity), through to intellectual ability, at an average age of 39
months.18 This suggests a cascading risk pathway from
genetic mutation to intellectual outcome in early child-
hood. The pathway leading to variability in intellectual
outcomes in the longer term (beyond early childhood) is
not well mapped; this has clinically relevant implications
for identifying early predictors of later developmental out-
comes.
We aimed to build on previous work by investigating:
(1) the distribution of IQ and rates of intellectual disability
later in childhood and adolescence in individuals with
TSC and unaffected siblings; (2) the effect of genetic
mutation as well as brain- and epilepsy-related risk factors
on long-term change in IQ over childhood and adoles-
cence, by grouping individuals according to a faster (in-
crease in IQ) versus slower (decrease in IQ) gain in skills;
and (3) multifactorial longitudinal pathways to individual
differences in intellectual ability in individuals with TSC
using structural equation modelling. We hypothesized that
early seizure severity would mediate the relationship
between genetic mutation and long-term intellectual out-
comes in TSC.
METHOD
Participants
The Tuberous Sclerosis 2000 Study is a population-based,
prospective, longitudinal study of the natural history of
TSC (for full details, see Yates et al.2 and Appendix S1,
online supporting information). In phase 1 of the study
(2001–2005), 125 participants met the diagnostic criteria
for TSC at 0 to 16 years old and completed the study
assessments (63 females, 62 males, median age=39mo,
range=4–254mo). At the initial assessment, a full medical
history was obtained and a physical examination carried
out using a standardized protocol. Full details of the study
assessment protocol have been reported elsewhere.2 During
phase 2 of the study (2012–2015), research psychologists
gathered information on the intellectual abilities of 88 par-
ticipants (49 females, 39 males, median age=148mo,
range=93–323mo), at an average of 8 years 4 months (5y
6mo–10y 10mo) after phase 1. In addition, to control for
potential familial influences on intellectual outcome, 35
unaffected siblings (14 females, 21 males, median
age=145mo, range=78–259mo) participated in phase 2 of
the study. Nineteen siblings were recruited from seven
families (17 full siblings, 1 half-sibling, and 1 dizygotic
twin).
Measures
Genetic testing
A causal mutation was determined for 96 children (TSC1,
n=19; TSC2, n=77). A pathogenic mutation could not be
identified in seven children; genetic testing was not carried
out in 22 children.
Brain imaging
Copies of clinical brain scans were obtained from the hos-
pitals where imaging had been conducted during phases 1
and 2, whenever possible (n=109; Appendix S1). The scans
were reviewed and rated without knowledge of other clini-
cal details by Nicholas Higgins (phase 1) and Fintan
Sheerin (phase 2) using a prespecified coding system that
recorded the number and lobar location of cortical tubers
and subependymal nodules. The interrater reliability of
this procedure has previously been shown to be accept-
able.19 Tuber count was summated for each major lobe of
the brain (Figs S1 and S2, online supporting information).
Epilepsy severity
Using information derived from a specially devised inter-
view schedule, seizure diary, and medical records, epilepsy
features were combined to generate a seizure severity score
using the Early Childhood Epilepsy Severity Scale.20
Exploratory factor analysis was conducted to ascertain the
loadings of each Early Childhood Epilepsy Severity Scale
feature to severity scores (Fig. S3, online supporting
What this paper adds
• Intellectual disability was present in 57% of individuals with tuberous scle-
rosis complex (TSC).
• Those with TSC without intellectual disability had significantly lower mean
IQ compared to unaffected siblings.
• Earlier onset and greater severity of seizures in the first 2 years were
observed in individuals with a slower gain in intellectual ability.
• Risk pathways through seizures in the first 2 years predict long-term cogni-
tive outcomes in individuals with TSC.
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information), with the following parameters loading onto
one factor: number of seizure types; time over which sei-
zures occurred (duration); seizure frequency at most severe;
number of antiepileptic drugs used; and treatment response.
Severity scores were calculated for four time points: the first
year of life (n=120); the second year of life (n=120); the
3-month period leading up to the phase 1 assessment
(n=125); and the 3-month period leading up to the phase 2
assessment (current seizure severity; n=94). To disentangle
the effect of epileptic spasms from other seizure types (in-
cluding generalized and focal seizures, defined using Inter-
national League Against Epilepsy classification) on
intellectual outcome, spasm severity was separately coded
from ‘non-spasm seizure severity’ for the first and second
year of life, when spasms tend to occur (Appendix S1).
Intellectual ability and adaptive behaviour
Following previous work,12,17 an estimated IQ was avail-
able for 121 participants in phase 1 and 88 in phase 2
(Appendix S1). In phase 1, intellectual abilities were
assessed using the Mullen Scales of Early Learning in par-
ticipants up to 68 months of age21 or the Vineland Adap-
tive Behavior Scales extended survey parental interview.22
In phase 2, participants were administered the Wechsler
Abbreviated Scale of Intelligence, Second Edition,23 British
Picture Vocabulary Scale,24 and/or the Vineland Adaptive
Behavior Scales, Second Edition.25
Statistical analysis
Factor scores resulting from factor analysis of tuber load
and seizure severity were used in group analyses and struc-
tural equation modelling (Figs S2 and S3).
Distribution of IQ in participants with TSC and their
unaffected siblings
Group differences in the estimated IQ of individuals with
TSC and unaffected siblings were analysed with t-tests in
Stata 10 (StataCorp LLC, College Station TX, USA) using
a robust cluster command to estimate standard errors,
which takes non-independent observations into account.
Factors associated with developmental change in
intellectual ability in TSC
Grouping according to developmental change in skills was
defined by a significant change in IQ from phase 1 to 2
(+15 IQ points for a faster gain in skills, 15 IQ points
for a slower gain in skills). Mann–Whitney U tests for
non-normally distributed data were conducted with group
(faster vs slower gain in skills) as the between-participant
variable and risk factor (e.g. seizure severity) as the depen-
dent variable. Participants with no significant change in IQ
were not included in the group comparisons; descriptive
data are provided in Table S1 (online supporting informa-
tion). v2 tests were used to examine the association
between mutation and history of epileptic spasms on
change. Spearman’s correlations were calculated between
change in IQ and ordinal epilepsy parameters. Group
differences in estimated IQ (normally distributed) by his-
tory of epileptic spasms and status epilepticus were tested
by analysis of variance.
Longitudinal risk pathways to intellectual outcomes in
TSC
Structural equation modelling was conducted using an
indirect mediation model in MPlus v7.31 (Muthen &
Muthen, Los Angeles, CA, USA). Factor scores for spasm
and non-spasm severity in years 1 and 2 were loaded onto
latent variables. Factor loadings for tuber load and seizure
severity, and raw scores for estimated IQ in phases 1 and
2 were entered as measured variables. To account for
missing values, full information maximum likelihood esti-
mation with robust standard errors was used. The boot-
strap model (1000 resamples) was used to estimate the
standard errors of the parameter estimates and the bias-
corrected confidence intervals (CIs) of the indirect effects.
The estimated indirect pathways were restricted by only
considering indirect pathways where there was a significant
coefficient for each path. Indirect effects were considered
statistically significant if the corresponding 95% CI did
not include zero.
Ethical approval
A medical ethics committee (NRES West Midlands – Edg-
baston) approved the study protocol. Written informed
consent was obtained from all study participants and/or
their caregivers before the assessments began.
RESULTS
Distribution of IQ in individuals with TSC and unaffected
siblings
The mean estimated IQ at phase 1 in participants with
TSC was 67.4 (range 20–132), with 62.4% (n=78) under
70 (indicating intellectual disability). The mean estimated
IQ at phase 2 in participants with TSC was 68.1 (range
26–119), with 56.8% (n=50) under 70 (Fig. 1). No individ-
ual had profound disability (estimated IQ ≤20), 11.4%
(n=10) had severe intellectual disability (20–34), and 45%
(n=40) had mild-to-moderate intellectual disability (35–70).
We compared the IQ scores of individuals with TSC
with an IQ in the typical range (>69; n=38; 21 females,
17 males, median age=161mo, range=93–323mo), with
those of unaffected siblings (n=35; 14 females, 21 males;
median age=145mo, range=78–259mo; Fig. 2). The mean
IQ of unaffected siblings (mean=110.06, SD=15.12) was
significantly higher than the TSC population
(mean=91.26, SD=13.18, t=5.60, p<0.001, d=1.33). The
difference was retained in individuals with TSC who did
not have current seizures (n=22; mean=92.00, SD=13.28,
t=4.58, p<0.001, d=1.27) or a history of spasms (n=25;
mean=93.12, SD=13.67, t=4.62, p<0.001, d=1.18). There
was an association between IQ in unaffected siblings and
maternal education level, a proxy for socio-economic sta-
tus (n=25; r=0.66, p=0.001), but not in TSC (n=28;
r=0.02, p=0.94).
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Factors associated with developmental change in
intellectual ability in TSC
Of the 85 individuals with IQ data at both phases 1 and 2,
50 participants (58.8%) had no significant change (<15
points) in IQ, 16 showed a relative decrease (18.8%), and
19 showed a relative increase (22.4%). There was no dif-
ference in point change in IQ based on intellectual disabil-
ity status at phase 1 (no intellectual disability=2.72,
intellectual disability=1.12; F[1,82]=0.88, p=0.35). A rela-
tive decrease in IQ may represent slower gain in intellec-
tual ability during development, rather than loss of skills
or developmental plateauing; hereafter, this group is
described as showing a slower gain in skills. Individuals
with a significant change in IQ (decreased vs increased;
n=35) were compared on a range of potential risk factors
(Table S2). The group with a slower gain in intellectual
ability showed a higher likelihood of history of status
epilepticus, younger age at seizure onset, and increased
severity of non-spasm seizures in the first 2 years of life,
compared to the group with a faster gain in ability. Age at
seizure onset (q=0.38, p=0.001), history of epileptic spasms
(F[1,86]=10.95, p=0.001), and history of status epilepticus
(F[1,86]=14.59, p<0.001) were each significantly associated
with lower estimated IQ at phase 2. Multivariate linear
regression indicated that among these three predictors, age
at seizure onset (b=0.26, p=0.02) and status epilepticus
(b=0.25, p=0.02) were the most strongly associated with
estimated IQ; in their presence, a history of spasms was no
longer significantly associated (b=0.13, p=0.25). Partici-
pants with seizure onset after 12 months of age had higher
IQ (75.77) at phase 2 compared to participants with seizure
onset under 12 months of age (65.02; t[80]=2.50, p=0.02,
d=0.65).
Using point change in IQ as a dimensional measure,
there was a significant correlation with age at seizure onset
(q=0.33, p=0.003), severity scores for non-spasm seizures
in years 1 (q=0.42, p<0.001) and 2 (q=0.25, p=0.02), and a
trend approaching significance towards increased tuber
load (q=0.22, p=0.05). No other correlations were signifi-
cant (all p>0.05).
Longitudinal risk pathways to intellectual outcome
Bivariate correlations between variables and phase 2 IQ are
provided in Tables S2 and S3 (online supporting informa-
tion). A ‘saturated’ model including all direct and indirect
paths linking the constructs of interest was tested. The
model yielded a good fit to the data (v2[24]=43.31,
p=0.009, root mean square error of approximation=0.08
(90% CI=0.04–0.12); standardized root mean square resid-
ual=0.06, comparative fit index=0.98). All significant direct
paths are shown in Fig. 3.
Three indirect paths were significant: (1) the strongest
pathway was indicated through the type of genetic muta-
tion, through tuber load, through non-spasm seizure sever-
ity in the first 2 years of life, and through to IQ at phase 2
(b=4.81, 95% CI=9.78 to 1.40), explaining 38% of
the total indirect effects between genetic mutation and IQ
at phase 2 when all pathways were included (72% when
restricted to significant pathways only); (2) mutation,
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Figure 1: Distribution of intellectual ability in phase 2 of the Tuberous
Sclerosis 2000 Study.
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Figure 2: Distribution of intellectual ability in participants with tuberous
sclerosis complex (TSC) with an IQ greater than 69 and unaffected sib-
lings.
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through tuber load, through non-spasm seizure severity,
through phase 1 IQ, through to phase 2 IQ (b=1.14,
95% CI=3.05 to 0.41); and (3) through mutation,
through tuber load, through spasm severity, through phase
1 IQ, and through to phase 2 IQ (b=0.72, 95%
CI=3.05 to 0.41). Comparisons of these indirect effects
revealed that pathway 1 through non-spasm seizure sever-
ity, through to IQ at phase 2 was significantly larger than
pathway 2 through non-spasm seizure severity, through to
IQ at phase 1 (b=1.31, 95% CI=0.51–3.35), and pathway 3
through tuber load, through to epileptic spasms and IQ at
phase 1 (b=0.84, 95% CI=0.31–2.14). Given the effect of
age at seizure onset on the trajectories of intellectual devel-
opment, age at seizure onset was included in a supplemen-
tary model; this replicated the same indirect pathways
while controlling for the effects of age at onset (Fig. S4
and Appendix S2, online supporting information). To con-
firm the validity of the estimated IQ, two additional mod-
els were executed using: (1) scores derived from the
Mullen Scales of Early Learning only at phase 1 and the
Wechsler Abbreviated Scale of Intelligence, Second Edi-
tion only at phase 2; and (2) Vineland Adaptive Behavior
Scales scores only from both phases (Figs S5 and S6,
online supporting information). The first model indicated
three of the same significant indirect pathways (1, 2, and 4)
linking genetic mutation through to IQ at phase 2
described earlier (Appendix S3 and Fig. S5, online support-
ing information). The second model indicated different
distinct pathways linking genetic mutation to adaptive abil-
ity at phase 2, with the largest effects shown for a pathway
linking type of genetic mutation, through cortical tuber
load, through to adaptive ability at phase 2, and epileptic
spasms through to adaptive ability at phase 2 (Appendix S4
and Fig. S6, online supporting information). We ran a fur-
ther model to estimate pathways to phase 1 IQ only
(Appendix S5 and Fig. S7, online supporting information),
indicating pathways through both non-spasm and spasm
severity; this confirmed our previous findings.18
DISCUSSION
This is the first study to explore long-term risk pathways to
intellectual outcome in individuals with TSC, by examining
the interaction between clinical risk factors on the trajecto-
ries of intellectual development. The findings demonstrate a
robust effect of epilepsy severity in the first 2 years of life,
particularly for seizures other than epileptic spasms. This
finding holds both when examining change in IQ over an
average period of 8 years, and when applying structural
equation modelling to explore the indirect longitudinal
pathways linking genetic mutation to intellectual ability.
Lower IQ was demonstrated in individuals with TSC
compared to unaffected siblings, and IQ scores were
TSC1 vs TSC2 Tuber load
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Figure 3: Full mediation model: the paths linking genotype and intellectual outcomes, through tuber load and epilepsy severity, are shown. The ovals
represent latent variables, the rectangles observed variables. Only significant paths are shown; absence of a line connecting variables implies no direct
effect (path was not significant). The standardized b for each path is shown; all paths shown are significant at p<0.05.
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truncated in the group with TSC, even in the more able
subgroup. Association with maternal education level, a
proxy for socio-economic status, was not indicated in the
group with TSC, suggesting lower IQ is not associated
with environmental factors and familial influences. This
suggests that specific genetic and/or neurological factors
are associated with intellectual impairment in individuals
with TSC, even in the absence of intellectual disability,
and override the effects of socio-economic status that are
seen in typically developing individuals. Intellectual ability
in individuals with TSC showed a unimodal distribution in
line with findings at a younger age in the same cohort18
but in contrast with other findings,4 which may reflect a
subset of individuals who experience further cognitive
decline into adulthood.26 A decrease in IQ from early
childhood to middle childhood/adolescence, which could
reflect either loss of or failure to gain skills over time, was
associated with earlier age at seizure onset and increased
seizure severity in the first 2 years of life, similar to previ-
ous retrospective studies.12,17 It is important to conduct
follow-up IQ assessments as cohort members transition to
adulthood to track further changes in developmental trajec-
tories.
Importantly, this work extends previous research by
mapping the pathways between the type of genetic muta-
tion and IQ across development, while reproducing the
risk pathways to short-term IQ. Lower Wechsler Abbrevi-
ated Scale of Intelligence, Second Edition scores were
demonstrated in patients with a TSC2 versus TSC1 muta-
tion (Table S3), which was not indicated for the Vineland
Adaptive Behavior Scales, Second Edition or estimated IQ.
This probably reflects the reduced sample size of partici-
pants completing the Wechsler Abbreviated Scale of Intel-
ligence, Second Edition and lower frequency of TSC1
mutations. Sophisticated structural equation modelling
indicated a significant indirect pathway linking the type of
genetic mutation (TSC2), to increased tuber load, to
increased severity of seizures in the first 2 years of life,
through to intellectual ability in middle childhood and
adolescence. This suggests that the association between
genetic mutation and long-term intellectual outcome is
mediated by tuber burden and seizure severity in the early
years, while controlling for current seizure severity. How-
ever, three additional pathways were indicated. First,
through early seizure severity and intellectual ability at
phase 1 of the study, which supports our previous find-
ings18 and suggests seizure severity may operate through
childhood intellectual ability; for a subset of individuals,
this remains relatively stable. Second, we observed two
pathways operating through epileptic spasm severity to
intellectual ability at phase 1 through to intellectual ability
at phase 2, which suggests that spasms have a direct effect
on short-term intellectual outcomes, in line with previous
work.16 Yet, the long-term effects of epileptic spasm treat-
ment on cognitive ability have also been demonstrated.13
Therefore, our finding could reflect the evolution of non-
spasm seizures to spasms in the early years, or the effect of
additional unmeasured variables. Furthermore, spasm
severity may show a greater effect on other developmental
outcomes in individuals with TSC, such as adaptive func-
tioning rather than general cognitive ability (supported in
Appendix S4 and Fig. S6) and symptoms of autism spec-
trum disorder. These effects should be systematically
explored through repeated assessment of infants with TSC
recruited before seizure onset, particularly since it is diffi-
cult to discriminate reliably between spasm and non-spasm
seizures.
The demonstration of multiple longitudinal pathways to
intellectual outcome may reflect varied and unique devel-
opmental trajectories based on risk factors and phenotypic
expressions, which may support more specific and targeted
therapeutic strategies. Still, the findings converge to sup-
port the major contributory role of early seizure severity
on outcome; thus, controlling seizures in the first 2 years
of life may be key for long-term intellectual development,
as supported by improved short-term outcomes for infants
treated early13 or preventatively based on epileptic
discharges on electroencephalography.27 Recent findings
support the predictive validity of certain electroen-
cephalography biomarkers on subsequent seizure onset in
infants with TSC,28 which demonstrates the potential value
of targeting treatments before the onset of epilepsy.
Results from early treatment trials will also provide insight
into the causal nature of the identified risk pathways that
are mediated by early seizure severity.
Several limitations should be taken into account. First,
the majority of brain imaging data were derived from
routine clinical investigations undertaken at different
points during development using different procedures.
While tuber load was a key determinant of seizures dur-
ing the early years, consistent with previous research,12
separating epilepsy-related intellectual disability from that
as a consequence of tubers is a challenge, since tubers
may not only cause intellectual disability but also hold
epileptogenic capability. It is important to conduct in-
depth neurological assessments to determine whether the
risk incurred by seizure severity is acting as a marker for
unmeasured brain abnormalities, such as altered connec-
tivity between brain regions that cannot be observed on
conventional magnetic resonance imaging.29 Second, there
was no direct pathway linking the type of genetic muta-
tion to epilepsy severity or intellectual outcome. Although
not inconsistent with previous studies, it is important to
conduct further genetic analyses since certain types of
mutations within TSC1 and TSC2 can result in varying
disease severity.5 Third, different measures were used to
measure intellectual ability because of a wide age and
ability range, and follow-up assessments were conducted
at different intervals. Nevertheless, associations in the
predicted direction across analyses have been shown, sug-
gesting robust associations regardless of measurement
error. This warrants replication within larger, prospective,
longitudinal studies with systematic assessments through-
out development.
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This study demonstrates a cascading longitudinal path-
way from gene to tuber load to early epilepsy severity
through to long-term intellectual ability. These findings
warrant the early detection and control of seizures as well
as regular neurocognitive assessments and support to
improve the intellectual outcomes of individuals with TSC
and other early-onset epilepsy syndromes.
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